Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2026

Conditions
Langerhans Cell Histiocytosis
Interventions
DRUG

Clofarabine

second-generation purine nucleoside analog

Trial Locations (15)

10029

Mount Sinai Medical Center, New York

19104

The Children's Hospital of Pennsylvania, Philadelphia

20010

Children's National Medical Center, Washington D.C.

38105

St. Jude Children's Research Hospital, Memphis

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

72202

Arkansas Children's Hospital, Little Rock

77030

Texas Children's Hospital, Houston

85016

Phoenix Children's Hospital, Phoenix

90027

Children's Hospital of Los Angeles, Los Angeles

94143

University of California San Francisco Medical Center, San Francisco

02114

Massachusetts General Hospital, Boston

02115

Boston Children's Hospital, Boston

Dana-Farber Cancer Institute, Boston

02215

Dana-Farber Cancer Institute, Boston

M5G 1X8

The Hospital for Sick Children, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

St. Baldrick's Foundation

OTHER

collaborator

Cookies for Kids' Cancer

OTHER

collaborator

North American Consortium for Histiocytosis

OTHER

lead

Dana-Farber Cancer Institute

OTHER